Skip to main content

Table 2 Prognostic analysis of DFS and OS for GISTs of the small intestine in terms of clinical features

From: Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate

Variable   Mean DFS (months; 95%CI of mean) P Mean OS (months; 95%CI of mean) P
Gender Male (N = 43) 60.0 (42.3–77.6) 0.2789 83.7 (63.0–105.5) 0.3171
  Female (N = 42) 84.3 (53.3–115.3)   108.5 (77.8–139.1)  
Age (years) 60 (N = 60) 66.9 (52.1–81.7) 0.3860 98.3 (79.57–117.1) 0.2646
  > 60 (N = 25) 68.8 (34.0–103.6)   93.7 (53.3–134.0)  
Operation time Elective (N = 61) 69.4 (46.6–92.1) 0.5463 100.5 (75.8–125.2) 0.6959
  Non-elective (N = 24) 73.6 (51.3–96.0)   85.3 (61.8–108.8)  
Operative procedure small intestine resection (N = 78) 68.3 (49.5–87.2) 0.1630 95.5 (74.8–116.2) 0.4290
  local excision (N = 7) 77.0 (54.7–99.2)   76.2 (53.1–99.3)  
Location Duodenum (N = 17) 52.3 (31.8–72.7) 0.6391 131.4(95.6–167.1) 0.5399
  Jejunum (N = 52) 68.6 (53.2–84.0)   85.2 (67.1–103.3)  
  Ileum (N = 16) 66.8 (24.4–09.2)   96.4 (49.2–143.7)  
Tumor size 2–5 cm (N = 15) 105.1 (79.1–131.) 0.0450 135.7 (101.2–170.2) 0.2413
  5–10 cm (N = 36) 61.5 (42.5–80.6)   78.9 (53.3–104.5)  
  > 10 cm (N = 34) 67.6 (38.8–96.5)   99.8 (64.9–134.6)  
Mesenteric involvement no (anti-mesenteric site) (N = 38) 82.5 (48.7–116.3) 0.7648 108.6 (70.2–146.9) 0.6855
  yes (mesenteric site) (N = 47) 62.3 (46.0–78.5)   89.6 (67.7–111.5)  
Local invasion No (N = 65) 82.4 (56.5–108.3) 0.0169 102.9 (76.8–129.0) 0.7962
  Yes (N = 20) 41.9 (20.6–63.2)   90.1(60.7–119.5)  
Tumor perforation No (N = 75) 75.7 (55.0–96.5) 0.0485 102.7 (80.8–124.8) 0.0594
  Yes (N = 10) 30.5 (15.1–45.9)   44.3 (29.7–59.0)  
  1. DFS = disease-free survival; OS = overall survival; GISTs = gastrointestinal stromal tumors